Results 101 to 110 of about 15,373 (177)

Identification of fulvestrant analogues for estrogen receptor alpha binding in breast cancer using molecular docking and molecular dynamics simulation

Discover Chemistry
Breast cancer remains a major global health challenge, with approximately 80% of cases classified as estrogen receptor-positive (ER+). Fulvestrant, a steroidal antiestrogen and selective estrogen receptor degrader (SERD), is widely used in ER+ breast ...
Atharva Balpande, Anushka Dashputra, Nikhil Khanwani, Yashasvi Therkar, Aryan Wasewar, Ganesh C. Patil, C. Ravikumar   +6 more
doaj   +1 more source

Everolimus Enhances the Efficacy of Fulvestrant in ER+ Breast Cancer

, 2018
mTOR inhibition with everolimus extends progression-free survival in combination with fulvestrant.

core   +1 more source

Characterizing safety, toxicity, and breast cancer risk reduction using a long-term fulvestrant eluting implant

Scientific Reports
For individuals at high risk of developing breast cancer, interventions to mitigate this risk include surgical removal of their breasts and ovaries or five years treatment with the anti-estrogen tamoxifen or aromatase inhibitors.
Scott Thomas, Elysia Roche, Pujan Desai, Nela Pawlowska, Diana Bauer, David Gingrich, Emily Hsu, Amelia N. Deitchman, Fran Aweeka, Pamela N. Munster   +9 more
doaj   +1 more source

Response to fulvestrant in heavily pretreated postmenopausal women:a single-center experience

, 2004
Fulvestrant (`Faslodex') is a new estrogen receptor (ER) antagonist that has no agonist effects. It binds, blocks and accelerates degradation of the ER, leading to a complete abrogation of estrogen-sensitive gene transcription.
Tan-chiu, Elizabeth, Frankel, Cynthia, Franco, Sandra, Perez, Alejandra, Vogel, Charles   +4 more
core   +1 more source

Fulvestrant in the management of postmenopausal women with advanced, endocrine-responsive breast cancer

, 2011
Fulvestrant is a pure estrogen antagonist that binds, blocks and downgrades the estrogen receptor (ER). Its unique mechanism of action is its antitumor activity after progression on prior endocrine therapy. Fulvestrant has shown activity in ER-dependent
Catherine Oakman, Libero Santarpia, Erica Moretti, Angelo Di Leo   +3 more
core   +1 more source

Role of fulvestrant in the treatment of postmenopausal metastatic breast cancer patients

, 2016
Introduction: Endocrine therapy is considered the cornerstone treatment for postmenopausal women with hormone-receptor positive metastatic breast cancer.
Lambertini, Matteo, Lambertini M, Levaggi, Alessia, Del Mastro L, Vaglica M, Poggio, Francesca, Del Mastro, Lucia, Pronzato, Paolo, Poggio F, Blondeaux, Eva, Vaglica, Marina, Levaggi A   +11 more
core   +1 more source

Cold atmospheric plasma restores fulvestrant sensitivity by inhibiting CCND3 in the drug-resistant breast cancer cells

Scientific Reports
Cold atmospheric plasma (CAP) has demonstrated anti-proliferative activity in various cancer cells, yet its efficacy against drug-resistant cancer cells remains largely unexplored.
Sooseong Choi, Sanghyun Jung, Hyeon Woo Kim, Hyeonjin Lee, Siyeon Jang, Minjae Baek, Seung-Hoon Yang, Eun Ha Choi, Sun Jung Kim   +8 more
doaj   +1 more source

Genome-wide shRNA screening identifies genes involved in fulvestrant resistance in breast cancer [PDF]

, 2016
Breast cancer accounts as the most prevalent cancer and the leading cause of cancer death worldwide among women. Estrogen is one main factor responsible for tumour growth in breast cancer patients through stimulation of estrogen receptor (ER) signalling.
Ramos, Pedro André Dias
core  

Determination of Fulvestrant in Pharmaceutical Preparation by Square Wave and Differential Pulse Voltammetry Methods

, 2015
In this study, simple and fast square wave voltammetry (SWV) and differential pulse voltammetry (DPV) methods were developed and validated for determination of fulvestrant in pharmaceutical preparation.
ATİLA, Alptuğ, YILMAZ, Bilal
core  

Alpelisib (Kombination mit Fulvestrant)

Diese frühe Nutzenbewertung von Alpelisib (Piqray®) in Kombination mit Fulvestrant ist ein weiteres Verfahren zu einem neuen Arzneimittel beim metastasierten Mammakarzinom.
Bleckmann, Annalen, Wörmann, Bernhard, Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie, Deutschland. Gemeinsamer Bundesausschuss   +3 more
core   +1 more source